Navigation Links
Inclinix-PMG Holdings, Inc. Announces Executive Management Changes
Date:7/11/2012

WILMINGTON, N.C. & WINSTON-SALEM, N.C., July 11, 2012 /PRNewswire/ -- Inclinix-PMG Holdings, a global clinical trial site and patient recruitment organization, today announced changes to the executive management team.

Dr. John Rubino of Raleigh Medical Group (RMG) has been appointed Medical Director of Inclinix-PMG Holdings, Inc. and also will serve as the head of the Principal Investigator Advisory Board. Dr. Rubino has been actively involved in clinical research for the past 22 years, and has been a Principal Investigator in over 600 trials. He was instrumental in developing clinical research in association with RMG and will lend his experience and expertise in clinical research to the Inclinix-PMG Holdings organization. Dr. Rubino says, "I look forward to helping meld the strengths of both Inclinix and PMG into the premier research organization by focusing on making our research efforts a win for patients, physicians and our research sponsors."

Jennifer Byrne has been named President and Chief Operating Officer of PMG Research Inc. Ms. Byrne has 25 years experience in the clinical research field. Through her various management roles, she has been influential in guiding the development and growth of PMG Research for the past 20 years, and will continue to do so in this capacity.

Denise Robinson has been named President and Chief Operating Officer of Inclinix, Inc. Ms. Robinson has over 15 years of pharmaceutical, clinical and healthcare experience. She has served in multiple leadership roles with Inclinix in her 10-year tenure and her experience and insight will provide valuable strategic direction for Inclinix.

"Together Inclinix and PMG Research bring forth an unrivaled precedent for research site-based experience which will allow for better outcomes for pharmaceutical sponsors, physician investigators, and research participants," says Ms. Byrne. Denise Robinson explains, "This merger is the great outcome of years of successful enrollment experience focused on supporting clinical research sites with innovative and effective patient recruitment solutions." 

"It is exciting to have this level of experience and industry knowledge leading the Inclinix and PMG Research divisions. We also are privileged to have the medical direction of Dr. Rubino supporting our efforts to make clinical trials a trusted treatment option for patients and physicians," states Inclinix-PMG Holdings, Inc. President and CEO, J. Tobin Geatz.

Inclinix-PMG Holdings, Inc. was formed by the strategic merger of Inclinix, Inc. with PMG Research Inc. in June 2012 with the vision to improve lives globally by making clinical trials a trusted treatment option for patients and physicians. Inclinix-PMG Holdings, Inc. strives to make clinical trials more available, accessible, and efficient with a commitment to Quality, Innovation, Integrity, and Community.

About PMG Research
PMG Research, Inc. is an Integrated Site Network based in Winston-Salem, NC. The staff and physicians at PMG Research have contributed to the development of numerous medications, medical devices and vaccines. PMG's mission is to provide unparalleled service to their clinical trial participants and pharmaceutical sponsors. www.pmg-research.com

About Inclinix
Inclinix, Inc. is a clinical trial enrollment solutions provider for pharmaceutical, biotechnology and medical device organizations based in Wilmington, NC. Clients benefit from twelve years of experience in multiple therapeutic areas. Inclinix delivers a customized, site-focused approach to patient recruitment ensuring every available study candidate is identified, qualified and enrolled. By combining an in-field approach with highly targeted patient outreach, Inclinix creates effective enrollment strategies within a performance model. www.inclinix.com 


'/>"/>
SOURCE Inclinix-PMG Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
2. Innophos Holdings, Inc. Reports First Quarter 2012 Results
3. China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 2012
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
6. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
7. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
8. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
9. WuXi PharmaTech Announces Third-Quarter 2011 Results
10. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
11. Spherix Announces Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):